Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Détails

ID Serval
serval:BIB_2BF0DD8008FD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
Périodique
Alzheimer's & dementia
Auteur(s)
Mattsson N., Groot C., Jansen W.J., Landau S.M., Villemagne V.L., Engelborghs S., Mintun M.M., Lleo A., Molinuevo J.L., Jagust W.J., Frisoni G.B., Ivanoiu A., Chételat G., Resende de Oliveira C., Rodrigue K.M., Kornhuber J., Wallin A., Klimkowicz-Mrowiec A., Kandimalla R., Popp J., Aalten P.P., Aarsland D., Alcolea D., Almdahl I.S., Baldeiras I., van Buchem M.A., Cavedo E., Chen K., Cohen A.D., Förster S., Fortea J., Frederiksen K.S., Freund-Levi Y., Gill K.D., Gkatzima O., Grimmer T., Hampel H., Herukka S.K., Johannsen P., van Laere K., de Leon M.J., Maier W., Marcusson J., Meulenbroek O., Møllergård H.M., Morris J.C., Mroczko B., Nordlund A., Prabhakar S., Peters O., Rami L., Rodríguez-Rodríguez E., Roe C.M., Rüther E., Santana I., Schröder J., Seo S.W., Soininen H., Spiru L., Stomrud E., Struyfs H., Teunissen C.E., Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G., Wallin Å.K., Wiltfang J., Vandenberghe R., Brooks D.J., Fladby T., Rowe C.C., Drzezga A., Verbeek M.M., Sarazin M., Wolk D.A., Fleisher A.S., Klunk W.E., Na D.L., Sánchez-Juan P., Lee D.Y., Nordberg A., Tsolaki M., Camus V., Rinne J.O., Fagan A.M., Zetterberg H., Blennow K., Rabinovici G.D., Hansson O., van Berckel BNM, van der Flier W.M., Scheltens P., Visser P.J., Ossenkoppele R.
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Statut éditorial
Publié
Date de publication
07/2018
Peer-reviewed
Oui
Volume
14
Numéro
7
Pages
913-924
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.
We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location.
The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education.
The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
Mots-clé
APOE, Age, Alzheimer's disease, Amyloid, CSF, Education, Geographical location, Mild cognitive impairment, PET, Prevalence, Sex, Subjective cognitive decline
Pubmed
Web of science
Création de la notice
03/04/2018 14:07
Dernière modification de la notice
15/08/2018 6:26
Données d'usage